Physician profile
Cameron Bonds
NPI 1699205989
$5,557.85
in general payments reported to CMS, 2019-2025
35 companies · $677 in 2025
The $677 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.36 · 2020: $216 · 2021: $1,030 · 2022: $1,226 · 2023: $1,326 · 2024: $1,047 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,049.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,038.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $578.82 | 2020-2025 | |
| Abbvie INC. | $557.66 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $386.78 | 2020-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $359.15 | 2020-2024 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.82 | 2021-2023 | Ofev, Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $333.46 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $277.62 | 2022 | |
| Lilly USA, LLC | $273.83 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $207.10 | 2020-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.58 | 2021-2024 | Xifaxan |
| Abbott Laboratories | $107.48 | 2021-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $103.66 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $83.97 | 2021-2023 | Linzess |
| Biohaven Pharmaceuticals, INC. | $81.58 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $66.20 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $59.14 | 2022-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $53.22 | 2022-2023 | Quviviq |
| Dexcom, INC. | $49.39 | 2022-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $40.44 | 2021-2022 | |
| Corcept Therapeutics | $40.13 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $37.75 | 2025 | Voquezna |
| Lundbeck LLC | $33.46 | 2025 | Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.10 | 2025 | Caplyta |
| Boston Scientific Corporation | $28.36 | 2022 | |
| Merck Sharp & Dohme LLC | $27.29 | 2021-2024 | Capvaxive |
| Neurocrine Biosciences, INC. | $26.75 | 2024 | Ingrezza |
| Amag Pharmaceuticals, INC. | $25.20 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.62 | 2024 | Austedo Xr |
| Mylan Specialty L.P. | $22.18 | 2021 | |
| Genentech USA, INC. | $18.13 | 2021 | |
| Sumitomo Pharma America, INC. | $16.72 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $15.76 | 2020 | |
| Exact Sciences Corporation | $14.36 | 2023 | Cologuard Collection Kit |
| Philips North America LLC | $13.34 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Bonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.